Abstract
The activated clotting time (ACT) is a commonly used method for assessing the degree of anticoagulation during cardiac surgery. Two automated ACT monitors were evaluated in 29 adult patients undergoing cardiac surgery. The HemoTec ACT monitor (HTC; HemoTec, Inc., Englewood, CO) was evaluated using 0.8 ml of whole blood in dualchamber, high range kaolin cartridges. The hemochron ACT monitor (HCH; International Technidyne, Inc, Edison, NJ) was evaluated using 2.0 ml of whole blood in glass tubes with diatomaceous earth activator. Following sternotomy, a coagulation profile consisting of HTC, HCH, and a partial thromboplastin time (PTT) was obtained (T0). Beef lung heparin was administered in 3 consecutive doses: 40 units/kg (T1), 80 units/kg (T2), and 180 units/kg (T3). Coagulation profiles were drawn 5 minutes after each dose. Following cardiopulmonary bypass (CPB), coagulation profiles were drawn 15 minutes (T4), 2 hours (T5), and 24 hours (T6) after the protamine dose. HTC and HCH ACT values differed significantly at T1, T2, and T4 (p<0.001). In the pre-CPB period, the HCH ACT correlation with PTT divided by its control value (PTT/CTL) (r=0.73) was significantly better (p=0.02) than the correlation of HTC ACT with PTT/CTL (r=0.41). In the post-CPB period, both HCH ACT (r=0.45) and HTC ACT (r=0.30) correlated weakly with PTT/CTL. In the bias analysis, the limits of agreement (of all HCH and HTC ACT values) showed that HTC ACT is between 61% and 133% of the HCH ACT value in 95% of determinations. These data contradict the results of a previous comparison of the two monitors, a study that suggested that HTC ACT overestimated anticoagulation at low heparin doses. HCH ACT correlated better than HTC ACT with the PTT values only in the pre-CPB period. The bias analysis indicates that even though the mean ACT values are usually close, there is considerable spread (−39 to +33%) when the 95% confidence intervals are calculated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hattersley PG. Activated coagulation time of whole blood. JAMA 1966;196:436–440
Bull BS, Korpman RA, Huse WN, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674–684
Cohen JA. Activated coagulation time method for control of heparin is reliable during cardiopulmonary bypass. Anesthesiology 1984;60:121–124
Jobes DR, Schwartz AJ, Ellison N, et al. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg 1981;31:161–166
Bull HS, Huse WN, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975;69:685–689
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–310.
Zahl K, Ellison N. An evaluation of three different ACT monitors. Abstracts of the 9th Annual Meeting, Society of Cardiovascular Anesthesiologists, May 10–13, 1988. Richmond, VA: Society of Cardiovascular Anesthesiologists, 1988:158.
Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg 1990;49:440–444
Culliford AT, Gitel SN, Starr N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981;193;105–111
Soloway HB, Christiansen TW. Heparin anticoagulation during cardiopulmonary bypass in an antithrombin-III deficient patient. Am J Clin Pathol 1980;73:723–725
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reich, D.L., Zahl, K., Perucho, M.H. et al. An evaluation of two activated clotting time monitors during cardiac surgery. J Clin Monitor Comput 8, 33–36 (1992). https://doi.org/10.1007/BF01618085
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01618085